Fostamatinib
Fostamatinib is an experimental drug candidate for the treatment of a variety of diseases, originally developed by Rigel Pharmaceuticals. The drug is administered orally as a disodium salt, and is a prodrug of the active compound tamatinib (R-406),
Fostamatinib has been in phase II trials for rheumatoid arthritis, autoimmune thrombocytopenia and lymphoma.
A phase II study of rheumatoid arthritis patients failing to respond to a biologic agent showed little efficacy as compared to placebo, but the drug was well tolerated. In patients with high inflammatory burden, measured by levels of C-reactive protein, ACR20 was achieved by a significantly higher portion of those in the fostamatinib group (42%) versus the placebo group (26%).
Liver safety of Fostamatinib
Fostamatinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to instances of clinically apparent acute liver injury.
Mechanism of action of Fostamatinib
Fostamatinib (fos" ta ma' ti nib) is an orally available, specific inhibitor of spleen tyrosine kinase that is used to treat chronic immune mediated thrombocytopenia. The spleen tyrosine kinase (Syk) signaling pathway is important in phagocytosis and specifically the antibody mediated uptake and destruction of platelets by splenic macrophages in patients with immune thrombocytopenia. The Syk signaling pathway may also play a role in other immune cell types involved in inflammation and cell damage.
FDA approval information for Fostamatinib
Fostamatinib was been shown to raise platelet counts in patients with refractory chronic immune thrombocytopenia and was approved for this use in the United States in 2018. Fostamatinib has also been evaluated in patients with rheumatoid arthritis, autoimmune hemolytic anemia and other immune-mediated conditions, but has not been specifically approved for these uses. Fostamatinib is available in tablets of 50 and 100 mg under the brand name Tavalisse.
Dosage and administration for Fostamatinib
The recommended initial dose is 100 mg twice daily, increasing to 150 mg twice daily after 4 weeks as needed.
Side effects of Fostamatinib
Common side effects include diarrhea, nausea, abdominal pain, hypertension, dizziness, chest pain, neutropenia and rash. Rare, but potentially severe adverse events include, severe diarrhea, hypertension, neutropenia and embryo-fetal toxicity.
Antihemorrhagics (B02) | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Hematologic Agents Eculizumab, Emapalumab, Emicizumab, Lanadelumab, Ravulizumab
Hematologic Growth Factors
- Granulocyte-Macrophage Colony Stimulating Factors
Thrombopoietin receptor agonists and Thrombopoiesis Stimulators
- Avatrombopag, Eltrombopag, Fostamatinib, Lusutrombopag, Romiplostim, Oprelvekin (IL-11)
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD